Engflag

Miralis

Quick links to important sections

Miralis

Miralis_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Miralis

What is Miralis? A Structured Definition

Property Description
Active Ingredient Standardized Vaccinium myrtillus extract
Form Oral preparation (e.g., capsule or tablet)
Pharmacological Class Vascular Protectant and Capillary Stabilizing Agent
Origin Natural, plant-derived (Herbal Medicine)

Miralis: Defining the Phyto-Pharmaceutical Class

Miralis is a specific phyto-pharmaceutical preparation derived from the extract of the Myrtillus fruit, commonly known as Bilberry (Vaccinium myrtillus). It is classified primarily as a Vascular Protectant and Capillary Stabilizing Agent, reflecting its action on the circulatory system. This is a recognized pharmacological designation for plant extracts that support vascular health; the dried Bilberry fruit extract is an established herbal substance used to support microcirculation. This preparation is a naturally sourced product, distinguishing it from purely synthetic agents.

Composition and the Active Ingredients (Anthocyanosides)

The efficacy of Miralis is intrinsically linked to the high concentration of its principal active ingredients: the anthocyanosides. These compounds are powerful polyphenolic compounds that are the key bioactive components quantified in the extract. The use of a standardized extract is a critical feature, assuring a consistent, quantified amount of anthocyanosides in the final oral preparation. Pharmacological studies have confirmed that these compounds are responsible for the key protective effects on the microvasculature.

General Purpose and Benefit as a Vascular Support Agent

The general purpose of Miralis is to provide foundational support for the integrity of the microcirculation and contribute to the maintenance of healthy vascular tone. The physiological actions of the anthocyanosides include functioning as potent antioxidants and helping to reinforce the walls of blood capillaries. Miralis is clinically recognized as a capillary stabilizing agent, which can be relevant in situations involving general venous insufficiency symptoms. By strengthening vessel structures and engaging in free radical scavenging, the preparation offers foundational support for circulatory tissues without specifying particular disease states.

What side effects are possible with Miralis?

Possible Side Effects and Safety Information: Miralis

The safety profile of Miralis (Polyethylene Glycol 3350) is formally structured around adverse reactions that primarily affect the gastrointestinal system, as documented in official regulatory labeling from sources like the FDA and NIH.

Adverse Reaction Scope and Classification

Adverse effects are categorized by frequency, which is consistent with regulatory standards for communicating incidence:

  • Common Reactions: The most frequently reported adverse events are related to Gastrointestinal Disorders. These include nausea, abdominal bloating or distension, flatulence, and abdominal cramping. These effects arise from the medicine's action in the digestive tract.
  • Rare or Not Known Reactions: The regulatory profile also documents the possibility of reactions involving the Immune System and Skin. These uncommon events include urticaria (hives) and other allergic-type responses.

Serious Adverse Reactions and Safety Constraints

Official labeling addresses specific, clinically significant safety concerns, even if they are infrequent:

  • Serious Hypersensitivity Reactions: Although rare, the potential for severe systemic allergic responses, such as anaphylaxis or angioedema, is documented. The appearance of such reactions necessitates immediate discontinuation of the medicine.
  • Safety Restriction (Contraindication): The medication is contraindicated and must not be used in individuals with a known or suspected bowel obstruction (intestinal blockage). This is a critical safety limitation defined in regulatory documents to prevent serious complications.
  • Population Guidance: Administration to the pediatric population requires supervision and specific guidance from a healthcare provider, according to regulatory notes.

The regulatory documentation emphasizes that while most reactions are common and localized, the safety profile is restricted by a mandatory exclusion criterion concerning intestinal blockage.

Overdose and Emergency Response

The regulatory overdose profile for Miralis (Polyethylene Glycol 3350) primarily focuses on the systemic consequences of excessive intake. Documented manifestations include severe diarrhea, excessive stool frequency, abdominal pain, nausea, vomiting, and abdominal distension.

The primary risk associated with overdose is excessive fluid loss, which can lead to life-threatening dehydration and electrolyte derangement. These imbalances may trigger serious complications affecting the Central Nervous System (CNS), such as confusion and seizures, or the Cardiovascular System, including cardiac arrhythmias.

Immediate emergency intervention is explicitly mandated by regulatory authorities under certain conditions. You must contact a Poison Control Center or seek medical help right away if an overdose is suspected. Immediate emergency services (911) should be called if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Temporary cessation or reduction of the dose is the typical initial measure for mild symptoms. Management for severe overdose is symptomatic and supportive, focusing on correcting fluid and electrolyte abnormalities; no specific antidote is known.

Overdose risk factors are noted for certain populations, including elderly patients, who are at a higher risk for developing severe dehydration and electrolyte disorders following excessive fluid loss. Caution is also advised for patients with a history of seizures or impaired kidney function.

Therapeutic Uses of Miralis

Main Uses of Miralis

Miralis is primarily utilized in the management of specific chronic conditions that affect metabolic and hormonal balance. Its clinical application is focused on stabilizing physiological processes that, when disrupted, lead to systemic symptoms.

Primary Indications

  • Hormonal Regulation: Miralis is indicated for patients requiring long-term stabilization of specific endocrine pathways. It works by modulating the production or reception of key signals within the body to maintain homeostasis.
  • Metabolic Support: The medication is used to address metabolic deficiencies that result in improper energy processing or nutrient utilization. By supporting these pathways, it helps prevent the complications associated with metabolic instability.
  • Symptom Management in Chronic Conditions: For individuals with certain persistent health issues, Miralis helps reduce the frequency and intensity of flare-ups, contributing to a more predictable health status.

Expected Benefits

The benefits of Miralis are observed through gradual physiological improvements rather than immediate symptom relief. The goal of treatment is to establish a consistent baseline for the patient.

Physiological Stabilization

The core benefit of Miralis is its ability to provide steady-state control of the targeted condition. This reduces the "peaks and valleys" often experienced with hormonal or metabolic disorders, leading to a more stable internal environment.

Improvement in Quality of Life

By managing the underlying mechanisms of a condition, Miralis can lead to several secondary benefits:

  • Enhanced Energy Levels: Proper metabolic regulation often results in more consistent energy throughout the day.
  • Systemic Balance: Effective modulation of hormonal levels can improve various bodily functions, including mood stability and sleep patterns.
  • Long-term Health Maintenance: Consistent use as directed can assist in slowing the progression of certain chronic markers, helping to maintain organ function over time.

Regulatory References

  1. NIH MedlinePlus guidance on Polyethylene Glycol 3350

Eligibility and Restrictions for Use

The official regulatory profile for Miralis (Polyethylene Glycol 3350) establishes clear guidelines on population eligibility, which determine who can and cannot use the medicine. These rules are derived strictly from government regulatory documentation.

The medicine is contraindicated and must not be used in patients with severe, acute gastrointestinal conditions. This includes known or suspected bowel obstruction, ileus, bowel perforation, toxic colitis, or toxic megacolon. Use is also prohibited for any individual with a confirmed allergy to polyethylene glycol.

Eligibility is defined by age and systemic status. The product is approved for use in adults and older adolescents 17 years of age and older. Safety and effectiveness have not been established in children under 17, and use in this group requires a healthcare professional's consultation.

Furthermore, use is restricted or conditional in certain populations. Patients with pre-existing renal impairment or uncorrected fluid and electrolyte imbalances must consult a doctor, as treatment requires caution. Pregnant or breastfeeding individuals are formally advised by regulatory labeling to ask a health professional before use. Caution is also required for patients with a history of seizures or those at risk for cardiac arrhythmias.

What should I know about interactions with other medicines?

Interaction Map: Miralis Interactions with other medicines and products

This section summarizes officially documented interaction information for Polyethylene Glycol 3350, the active ingredient in Miralis, based strictly on government regulatory sources.

Interaction Type Interacting Agents / Classes Restriction or Classification
Pharmacodynamic Risk Diuretics, ACE Inhibitors, ARBs, NSAIDs Use with Caution (Additive risk of fluid/electrolyte disturbance)
Gastrointestinal Risk Other Laxatives (e.g., Stimulant Laxatives) Use with Caution (Increased risk of colonic adverse events)
Physical Incompatibility Starch-Based Thickeners Restriction (Loss of viscosity)
Pharmacokinetic Risk None Documented (CYP Enzymes, Transporters) No Clinically Significant Interaction Demonstrated

Official Interaction Statements:

  • The regulatory profile confirms the absence of demonstrated drug-drug interactions mediated by metabolic enzymes or drug transporters due to minimal systemic absorption.
  • Co-administration with Diuretics, ACE Inhibitors, ARBs, or NSAIDs may increase the additive risk for fluid and electrolyte disturbances (e.g., hypokalemia, hyponatremia).
  • Other laxatives should be used cautiously due to the potential for increased gastrointestinal irritation and adverse events.
  • The product is physically incompatible with starch-based thickeners, resulting in a loss of thickness of the liquid.

Connection to the overall interaction profile: The drug's interaction profile is not defined by systemic metabolic effects but by its osmotic action in the gastrointestinal tract. Consequently, the primary regulatory concerns are pharmacodynamic, highlighting additive risks for fluid/electrolyte changes, and physical incompatibility with specific additives. No mandatory timing separation rules are required for the daily administration of this product.

Mechanism of Action

Miralis (mirogabalin) exerts its action by modulating voltage-gated calcium channels (VGCCs) in the nervous system, resulting in the adjustment of neural signaling output. The compound binds with high affinity to the alpha 2delta -1 subunit of these channels, which are expressed on the membranes of neurons, particularly within the dorsal root ganglia (DRG). This molecular interaction influences the trafficking and functional availability of the VGCCs.

This binding modifies the channel's activity, leading to a crucial decrease in the influx of calcium ions left( Ca^2+ ight) into the presynaptic nerve terminal. This reduction in calcium influx is the mechanistic cascade that inhibits the synaptic release of excitatory neurotransmitters, such as glutamate. By constraining the concentration and duration of released mediators, Miralis limits the escalation of signaling sequences, supporting the establishment of a modified steady-state signaling profile within the targeted pathways and leading to an altered physiological response profile based on VGCC engagement.

Dosage and Administration Information

How Miralis is Used: Administration Guidelines

Miralis (polyethylene glycol 3350) is used according to specific instructions for the management of occasional constipation. This standardized approach ensures consistent delivery of the medicine.

Administration Scope

Principle Instruction
Route Oral administration only.
Form Powder for oral solution, intended to be fully dissolved in liquid.
Standard Dose 17 grams of powder for individuals 17 years and older. The dose is to be taken once daily.
Timing May be taken at any time of day, with or without food.

Preparation and Duration Constraints

The correct preparation of the powder is essential for its proper use. The 17-gram dose must be stirred into and fully dissolved in 4 to 8 ounces of fluid, which may include water, juice, or coffee. The solution must be completely clear upon mixing and should not be consumed if any undissolved clumps of powder remain. A key procedural condition is that the powder must not be combined with starch-based thickeners.

For over-the-counter use, the duration is limited: Miralis should generally not be used for longer than seven consecutive days. If the condition persists after this timeframe, individuals must seek guidance from a healthcare provider. The established protocol emphasizes that for patients 16 years of age or under, use must be supervised by a doctor.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Miralis (Polyethylene Glycol 3350)

Evidence for Use in Occasional Constipation (Adults)

Research related to Miralis for short-term, occasional constipation in adults includes Randomized Controlled Trials (RCTs) and supporting documentation from regulatory bodies. These studies involved adults and adolescents aged 17 and older experiencing temporary symptoms of difficult bowel movements. Researchers focused on outcomes related to physical discomfort and acute changes, such as monitoring the time to a first bowel movement and tracking the change in weekly bowel movement frequency. Research highlights that outcomes related to stool consistency and the amount of straining were monitored in the observed populations during the defined study periods (typically seven to fourteen days). The evidence primarily explores short-term outcomes, and long-term data for this specific, brief pattern of constipation are not the primary focus of the research.

Evidence for Use in Chronic Constipation Management

Beyond occasional use, Miralis was evaluated in extensive research for the longer-term management of chronic or functional constipation. This evidence base consists of multiple RCTs, systematic reviews, and meta-analyses. Studies examined bowel function, and research tracked the measured physiological patterns over intermediate and longer time intervals, with some studies extending up to six months and, in some cases, for up to one year. The evidence monitored changes in bowel function, and findings report that the measured physiological patterns were observed throughout the study periods. While research describes long-term symptom patterns in groups with chronic use, specific comparisons against every alternative treatment across all existing studies are not uniform, and limited comparative evidence is available for some drug classes.

Research in Children and Adolescents

Research has explored the use of Miralis for functional constipation and the treatment of fecal impaction in children. These studies utilized RCTs and head-to-head comparisons against other agents. Researchers monitored outcomes related to functional measures, including the rate of clearance of fecal mass and the subsequent change in episodes of soiling. Data described patterns related to changes in bowel movement frequency. However, evidence is limited for certain groups, such as very young children (under two years of age), compared to data for older age groups. Research describes the use of this preparation in children, but it is not officially labeled by the FDA for those under 17.

Frequently Asked Questions (FAQ)

Common questions about Miralis (FAQ)

Q: How long does it typically take for Miralis to produce a bowel movement?

According to the official product information for Miralis, when used for occasional constipation, relief is generally observed within one to three days. Individual results may vary.

Q: What kind of liquid is NOT safe to mix Miralis powder with?

Regulatory documents explicitly state that Miralis powder must not be combined with starch-based thickeners, which can cause a physical incompatibility. For proper use, the powder must be completely dissolved in the chosen liquid, and the product information states that the solution should not be consumed if undissolved clumps remain.

Q: Does Miralis interact with any foods, or is it safe to take with meals?

Official administration guidelines for Miralis state that it may be taken at any time of day. This means the product can be taken either with or without food.

Q: Is there any official study evidence for Miralis use in toddlers or very young children?

Regulatory guidance emphasizes that the use of Miralis for children 16 years of age or under requires consultation with a healthcare provider. Safety and effectiveness for this age group have not been established in the official regulatory documentation.

Q: Where is Miralis metabolized, and how is it excreted from the body?

Miralis is classified as an osmotic agent, which works by attracting water into the stool. Clinical data indicates that the active ingredient is minimally absorbed into the body. Due to its minimal systemic absorption, official information indicates the product is recovered and leaves the body primarily through the stool.

Q: How do I know if the powder is fully dissolved and ready to drink?

The official directions require that the powder be fully stirred until it is completely dissolved and the solution is clear. If undissolved clumps of powder are present, the product information states the solution should not be consumed.

Q: I forgot to take my daily dose. What should I do?

The product is intended for once-daily use as needed for the relief of occasional constipation. Official information advises against taking more than the recommended dose.

Q: Is Miralis available as a tablet or liquid, or only as a powder?

According to the official product description, Miralis is supplied as a powder that must be mixed into a solution before being taken orally.

Q: Is Miralis a stimulant laxative?

No, Miralis is not classified as a stimulant laxative. The product information officially classifies its purpose as an osmotic laxative, which works differently by retaining water in the stool.

How should Miralis be stored and disposed of?

How to Store and Dispose of Miralis (Polyethylene Glycol 3350)

Official Storage Conditions

Miralis must be stored at Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat and moisture; therefore, storage in environments like the bathroom should be avoided. The medicine must remain in its original container, which must be kept tightly closed to maintain product integrity. If the tamper-evident seal under the cap is broken or missing, the product should not be used.

Child Safety and Disposal

It is a mandatory requirement to store Miralis strictly out of the sight and reach of children.

For disposal, expired or unused medication should be taken to an authorized drug take-back program. If no take-back option is available, the product can be safely disposed of in the household trash after mixing it with an unappealing substance like dirt or used coffee grounds, according to regulatory guidelines. This medicine is not on the list of drugs recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Miralis found in:

A-Z Index: